13 nov 2019 · Conclusions: AUTO3, a novel bicistronic anti CD19/CD22 CAR T therapy, has a manageable safety profile in combination with Pem. Notable is the ...

7 dic 2022 · AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL). It is an investigational ...

25 mag 2020 · KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R ...

AUTO3-DB1, Single-Arm, Open-Label, Multi-Center, Phase 1/2 Study ... AUTO3 program designed to address tumor escape mechanisms with a potential best-in-class ...

7 dic 2020 · AUTO3 at RP2D dose range of > 50 x 106 CAR T cells with D-1 pembrolizumab induces durable complete remissions. None of the patients in CR ...

A preparation of autologous T lymphocytes that have been transduced with a bicistronic retroviral vector encoding both an anti-CD19 chimeric antigen ...

13 nov 2019 · This interim data analysis demonstrates that AUTO3 at ≥3 x 106 cells dose achieved 100% molecular remission rate with a favourable safety ...

In this study, we evaluate the safety and efficacy of AUTO3, a CAR T-cell therapy designed to target CD19 and CD22 simultaneously in order to reduce the ...

AUTO 3 is a bicistronic chimeric antigen receptor T-cell therapy, being developed by Autolus, for the treatment of precursor cell lymphoblastic.

7 dic 2020 · AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been ...